argenx SE (NASDAQ:ARGX) Shares Purchased by Neuberger Berman Group LLC

Neuberger Berman Group LLC boosted its position in argenx SE (NASDAQ:ARGX) by 9.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 770 shares of the company’s stock after buying an additional 67 shares during the period. Neuberger Berman Group LLC’s holdings in argenx were worth $474,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Whipplewood Advisors LLC purchased a new stake in shares of argenx in the 4th quarter valued at $37,000. Global Retirement Partners LLC boosted its holdings in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd acquired a new stake in argenx during the 4th quarter worth about $38,000. Jones Financial Companies Lllp raised its stake in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after buying an additional 61 shares during the last quarter. Finally, Huntington National Bank lifted its holdings in shares of argenx by 1,133.3% in the 4th quarter. Huntington National Bank now owns 74 shares of the company’s stock valued at $46,000 after buying an additional 68 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

ARGX has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $720.00 target price on shares of argenx in a report on Tuesday. Sanford C. Bernstein raised shares of argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Piper Sandler increased their price target on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Oppenheimer lifted their price objective on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Finally, Truist Financial reissued a “buy” rating and set a $700.00 target price (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $690.33.

argenx Price Performance

Shares of argenx stock opened at $580.94 on Friday. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The stock has a market cap of $35.30 billion, a P/E ratio of -660.16 and a beta of 0.60. The stock’s 50 day simple moving average is $607.87 and its 200-day simple moving average is $603.90.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. As a group, research analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.